Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world
Background/Aims Previous studies have reported a high rate of sustained virologic response (SVR) and a low rate of serious adverse events with the use of daclatasvir (DCV) and asunaprevir (ASV) combination therapy. We evaluated the efficacy and safety of DCV and ASV combination therapy for patients...
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
The Korean Association of Internal Medicine
2019-07-01
|
Series: | The Korean Journal of Internal Medicine |
Subjects: | |
Online Access: | http://www.kjim.org/upload/pdf/kjim-2017-368.pdf |